CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Lyell Immunopharma, Inc. - LYEL CFD

2.58
15.41%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Lyell Immunopharma Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.05
Open* 2.95
1-Year Change* 34.09%
Day's Range* 2.51 - 2.95
52 wk Range 1.32-3.97
Average Volume (10 days) 1.48M
Average Volume (3 months) 27.27M
Market Cap 496.18M
P/E Ratio -100.00K
Shares Outstanding 251.87M
Revenue 48.50M
EPS -0.76
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date N/A

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 3.05 0.17 5.90% 2.88 3.19 2.87
Feb 29, 2024 2.91 0.20 7.38% 2.71 3.03 2.62
Feb 28, 2024 2.82 0.09 3.30% 2.73 2.91 2.71
Feb 27, 2024 2.82 0.09 3.30% 2.73 2.82 2.55
Feb 26, 2024 2.59 0.22 9.28% 2.37 2.59 2.33
Feb 23, 2024 2.37 -0.01 -0.42% 2.38 2.44 2.32
Feb 22, 2024 2.41 0.20 9.05% 2.21 2.44 2.21
Feb 21, 2024 2.26 0.24 11.88% 2.02 2.26 2.02
Feb 20, 2024 2.09 0.23 12.37% 1.86 2.09 1.86
Feb 16, 2024 1.84 0.02 1.10% 1.82 1.91 1.82
Feb 15, 2024 1.87 0.13 7.47% 1.74 1.87 1.74
Feb 14, 2024 1.75 0.04 2.34% 1.71 1.78 1.71
Feb 13, 2024 1.73 -0.08 -4.42% 1.81 1.85 1.71
Feb 12, 2024 1.91 0.13 7.30% 1.78 1.92 1.78
Feb 9, 2024 1.77 0.09 5.36% 1.68 1.80 1.67
Feb 8, 2024 1.68 0.00 0.00% 1.68 1.74 1.68
Feb 7, 2024 1.73 -0.10 -5.46% 1.83 1.84 1.73
Feb 6, 2024 1.85 0.12 6.94% 1.73 1.86 1.73
Feb 5, 2024 1.76 0.01 0.57% 1.75 1.77 1.69
Feb 2, 2024 1.78 -0.02 -1.11% 1.80 1.83 1.74

Lyell Immunopharma, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 84.683 10.65 7.756 0.657
Revenue 84.683 10.65 7.756 0.657
Total Operating Expense 276.741 261.873 219.693 102.746
Selling/General/Admin. Expenses, Total 117.307 89.057 46.881 39.151
Research & Development 164.318 134.98 182.243 63.595
Other Operating Expenses, Total -9.884 1.089 -9.431 0
Operating Income -192.058 -251.223 -211.937 -102.089
Interest Income (Expense), Net Non-Operating 5.986 0.909 5.939 8.121
Other, Net 2.954 0.095 1.526 -35.409
Net Income Before Taxes -183.118 -250.219 -204.472 -129.377
Net Income After Taxes -183.118 -250.219 -204.472 -129.377
Net Income Before Extra. Items -183.118 -250.219 -204.472 -129.377
Net Income -183.118 -250.219 -204.472 -129.377
Income Available to Common Excl. Extra. Items -183.118 -250.219 -204.472 -129.377
Income Available to Common Incl. Extra. Items -183.118 -250.219 -204.472 -129.377
Diluted Net Income -183.118 -250.219 -204.472 -129.377
Diluted Weighted Average Shares 249.567 242.738 242.83 242.83
Diluted EPS Excluding Extraordinary Items -0.73374 -1.03082 -0.84204 -0.53279
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -0.71371 -0.87943 -0.84204 -0.53279
Unusual Expense (Income) 5 36.747
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.027 0.065 48.386 0.003 35.741
Revenue 0.027 0.065 48.386 0.003 35.741
Total Operating Expense 68.855 72.621 63.17 71.44 73.002
Selling/General/Admin. Expenses, Total 19.03 19.279 26.348 26.084 30.454
Research & Development 47.471 46.338 45.339 39.166 40.132
Other Operating Expenses, Total -0.569 -2.996 -8.517 1.19 2.416
Operating Income -68.828 -72.556 -14.784 -71.437 -37.261
Interest Income (Expense), Net Non-Operating 5.264 4.497 3.453 1.17 0.938
Other, Net -0.326 1.1 2.934 0.013
Net Income Before Taxes -63.89 -66.959 -8.397 -70.254 -36.323
Net Income After Taxes -63.89 -66.959 -8.397 -70.254 -36.323
Net Income Before Extra. Items -63.89 -66.959 -8.397 -70.254 -36.323
Net Income -63.89 -66.959 -8.397 -70.254 -36.323
Income Available to Common Excl. Extra. Items -63.89 -66.959 -8.397 -70.254 -36.323
Income Available to Common Incl. Extra. Items -63.89 -66.959 -8.397 -70.254 -36.323
Diluted Net Income -63.89 -66.959 -8.397 -70.254 -36.323
Diluted Weighted Average Shares 250.204 249.591 259.414 248.32 246.312
Diluted EPS Excluding Extraordinary Items -0.25535 -0.26827 -0.03237 -0.28292 -0.14747
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.24367 -0.22821 -0.03237 -0.26278 -0.14747
Unusual Expense (Income) 2.923 10 0 5
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 651.295 626.286 617.547 440.259
Cash and Short Term Investments 640.152 614.794 612.619 436.049
Cash & Equivalents 123.554 293.828 140.406 96.674
Short Term Investments 516.598 320.966 472.213 339.375
Prepaid Expenses 11.143 11.492 4.928 4.21
Total Assets 937.561 1127.41 908.28 555.631
Property/Plant/Equipment, Total - Net 166.265 166.639 124.055 43.705
Property/Plant/Equipment, Total - Gross 198.649 181.152 129.159 44.961
Accumulated Depreciation, Total -32.384 -14.513 -5.104 -1.256
Long Term Investments 115.041 330.532 163.443 68.983
Other Long Term Assets, Total 4.96 3.949 3.235 2.684
Total Current Liabilities 37.028 46.738 49.285 22.045
Accounts Payable 3.917 3.207 9.396 2.844
Accrued Expenses 26.403 27.588 26.952 13.019
Notes Payable/Short Term Debt 0 0 0 0
Other Current Liabilities, Total 6.708 15.943 12.937 6.182
Total Liabilities 104.309 197.619 189.84 147.576
Total Long Term Debt 0 0 0 0
Other Liabilities, Total 67.281 150.881 140.555 125.531
Total Equity 833.252 929.787 718.44 408.055
Redeemable Preferred Stock 0 0 1010.97 519.163
Common Stock 0.025 0.024 0.002 0.001
Additional Paid-In Capital 1608.31 1515.75 41.357 18.108
Retained Earnings (Accumulated Deficit) -767.48 -584.362 -334.143 -129.671
Other Equity, Total -7.599 -1.623 0.256 0.454
Total Liabilities & Shareholders’ Equity 937.561 1127.41 908.28 555.631
Total Common Shares Outstanding 249.567 242.738 242.83 242.83
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 586.854 606.41 624.398 651.295 659.745
Cash and Short Term Investments 575.431 595.748 612.769 640.152 648.132
Cash & Equivalents 286.214 224.372 109.426 123.554 116.311
Short Term Investments 289.217 371.376 503.343 516.598 531.821
Prepaid Expenses 11.423 10.662 11.629 11.143 11.613
Total Assets 794.989 835.354 880.45 937.561 977.269
Property/Plant/Equipment, Total - Net 148.699 155.189 160.99 166.265 169.811
Long Term Investments 54.73 68.953 90.179 115.041 144.52
Other Long Term Assets, Total 4.706 4.802 4.883 4.96 3.193
Total Current Liabilities 35.064 34.39 30.797 37.028 51.217
Accounts Payable 4.365 5.805 5.733 3.917 4.795
Accrued Expenses 29.652 24.832 22.416 28.755 23.568
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 1.047 3.753 2.648 4.356 22.854
Total Liabilities 97.416 98.499 96.624 104.309 157.243
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 62.352 64.109 65.827 67.281 106.026
Total Equity 697.573 736.855 783.826 833.252 820.026
Redeemable Preferred Stock 0 0 0
Common Stock 0.025 0.025 0.025 0.025 0.025
Additional Paid-In Capital 1647.91 1637.54 1622.12 1608.31 1589.08
Retained Earnings (Accumulated Deficit) -949.182 -898.329 -834.439 -767.48 -759.083
Other Equity, Total -1.181 -2.379 -3.879 -7.599 -9.996
Total Liabilities & Shareholders’ Equity 794.989 835.354 880.45 937.561 977.269
Total Common Shares Outstanding 251.869 251.027 249.609 249.567 249.24
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -183.118 -250.219 -204.472 -129.377
Cash From Operating Activities -169.555 -126.249 -160.874 39.474
Cash From Operating Activities 18.02 13.624 4.294 1.256
Non-Cash Items 77.558 106.331 39.64 56.787
Changes in Working Capital -82.015 4.015 -0.336 110.808
Cash From Investing Activities -11.54 -121.573 -273.516 -422.433
Capital Expenditures -24.276 -65.504 -51.481 -16.047
Other Investing Cash Flow Items, Total 12.736 -56.069 -222.035 -406.386
Cash From Financing Activities 10.635 401.244 476.79 351.156
Issuance (Retirement) of Stock, Net 11.096 401.244 476.79 351.156
Net Change in Cash -170.46 153.422 42.4 -31.803
Financing Cash Flow Items -0.461
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -66.959 -183.118 -174.721 -104.467 -68.144
Cash From Operating Activities -46.212 -169.555 -129.288 -92.185 -47.852
Cash From Operating Activities 5.027 18.02 12.979 8.358 4.187
Non-Cash Items 20.031 77.558 71.076 44.295 18.494
Changes in Working Capital -4.311 -82.015 -38.622 -40.371 -2.389
Cash From Investing Activities 32.154 -11.54 -58.188 -1.103 -26.122
Capital Expenditures -1.533 -24.276 -19.694 -16.903 -9.733
Other Investing Cash Flow Items, Total 33.687 12.736 -38.494 15.8 -16.389
Cash From Financing Activities -0.069 10.635 9.772 5.012 2.555
Issuance (Retirement) of Stock, Net 0 11.096 10.139 5.012 2.555
Net Change in Cash -14.127 -170.46 -177.704 -88.276 -71.419
Financing Cash Flow Items -0.069 -0.461 -0.367
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
ARCH Venture Partners Venture Capital 14.5055 36412716 0 2023-03-31 LOW
GSK plc Corporation 12.0518 30253189 0 2023-03-31 LOW
MWG Management, Ltd. Investment Advisor 8.0319 20162332 0 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.713 16851453 4092330 2023-06-30 LOW
Apoletto Ltd Investment Advisor 6.0129 15093969 0 2022-09-30
Orland Properties Ltd Investment Advisor 6.0129 15093969 0 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 4.5021 11301579 764502 2023-06-30 LOW
Foresite Capital Management, LLC Private Equity 3.8641 9700000 -300000 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 3.2373 8126378 4192340 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 2.4584 6171245 -1750007 2023-06-30 LOW
Alphabet, Inc. Venture Capital 2.3365 5865125 0 2023-06-30 LOW
Bishop (Hans Edgar) Individual Investor 1.8666 4685614 0 2023-03-31 LOW
Klausner Richard Individual Investor 1.5762 3956734 -11100 2023-03-31 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3448 3375828 187393 2023-06-30 LOW
MIC Capital Management UK LLP Investment Advisor 1.2192 3060569 0 2023-06-30 LOW
SC China Holding Ltd Investment Advisor 1.2134 3045997 0 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.1411 2864448 -65757 2023-06-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 0.547 1373218 -18190 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.5185 1301656 47027 2023-06-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 0.4589 1152009 12535 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lyell Immunopharma, Inc. Company profile

About Lyell Immunopharma Inc

Lyell Immunopharma, Inc is a T cell reprogramming company. The Company offers T cells to cure patients with solid tumors. Its technologies are designed to be applied in a target and agnostic manner to chimeric antigen receptor (CAR), tumor-infiltrating lymphocytes (TIL) and T cell receptor (TCR) therapies to improve the properties of T cells to eradicate solid tumors. It builds a multi-modality product pipeline across solid tumor indications with unmet needs and anticipate having investigational new drug application (IND). It offers Gen-R and Epi-R technology platforms. Its Gen-R is its ex vivo genetic reprogramming technology to overcome T cell exhaustion. Its Epi-R is an ex vivo epigenetic reprogramming technology to create a population of T cells with durable stemness. Epi-R is designed to generate populations of T cells which have this property of durable stemness. It utilizes its Gen-R and Epi-R technology platforms to develop a multi-modality product pipeline.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Lyell Immunopharma Inc revenues increased 44% to $7.8M. Net loss increased 1% to $166.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $11.3M to $28.4M (expense), General and administrative - Balanc increase of 39% to $28.8M (expense).

Industry: Bio Therapeutic Drugs

201 Haskins Way
Suite 301
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

US100

18,215.30 Price
-0.390% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 7.0

Oil - Crude

78.48 Price
-1.270% 1D Chg, %
Long position overnight fee 0.0260%
Short position overnight fee -0.0479%
Overnight fee time 22:00 (UTC)
Spread 0.040

BTC/USD

67,467.00 Price
+7.250% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.65 Price
+2.970% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading